Metastatic rhabodmyosarcoma cured after chemotherapy and allogenic SCT

Bone Marrow Transplantation

Volumn 43, Issue 2, 2009, Pages 179-180

  Donker, A E ^a   Hoogerbrugge, P M ^a   Mavinkurve Groothuis, A M C ^a   van de Kar, N C A J ^a   Boetes, C ^a   Hulsbergen van de Kaa, C A ^a   Groot Loonen, J J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACTINOMYCIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE METASTASIS; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CAUCASIAN; FEMALE; GASTROCNEMIUS MUSCLE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; KIDNEY TUBULE DISORDER; LETTER; LYMPH NODE METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SCHOOL CHILD; TREATMENT OUTCOME; WHOLE BODY RADIATION; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM METASTASIS; REMISSION INDUCTION; RHABDOMYOSARCOMA; TRANSPLANTATION CONDITIONING;

EID: 59549099539     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.301     Document Type: Letter

References (9)

1. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C et al The third intergroup rhabdomyosarcoma study. J Clin Oncol 1995; 13: 610-630.
2. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM et al Prognostic factors and clinical outcome in children and adolescents with metastatic rhabdomyosarcoma-a report from the intergroup rhabdomyosarcoma study IV. J Clin Oncol 2003; 21: 78-84.
3. Carli M, Colombatti R, Oberlin O, Bisogno B, Treuner J, Koscielniak E et al. European intergroup studies (MMT 4-89 and NMT 4-91) on childhood metastatic rhabdomyosarcoma: Final results and analysis of prognostic factors. J Clin Oncol 2004; 22: 4787-4794.
4. Klingebiel T, Boos J, Beske F, Hallmen E, Int-Veen C, Dantonello T et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial. Pediatr Blood Cancer 2008; 50: 739-745.
5. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001; 5: 272-276.
6. Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: Directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8: 2-11.
7. Doelken R, Weigel S, Schueler F, Doelken G, Beck JF. Poor outcome of two children with relapsed state stage IV rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol 2005; 22: 699-703.
8. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A et al. Minimal residual disease status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with all. Leukemia 2002; 16: 1668-1672.
9. Misawa A, Hosoi H, Tsuchiya K, Iehara T, Sawada T, Sugimoto T. Regression of refractory rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol 2003; 20: 151-155.